{"id":18313,"date":"2021-10-27T11:06:39","date_gmt":"2021-10-27T09:06:39","guid":{"rendered":"https:\/\/www.izb-online.de\/gco_events\/izbrunch-november-2021\/"},"modified":"2022-07-05T10:41:13","modified_gmt":"2022-07-05T08:41:13","slug":"izbrunch-november-2021","status":"publish","type":"gco_events","link":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/","title":{"rendered":"IZBrunch November 2021"},"content":{"rendered":"

[vc_section el_class=”gco-layout-event”][vc_row][vc_column][vc_empty_space height=”21px”][vc_column_text]<\/p>\n

\n
\n
\n
<\/div>\n
\n
<\/div>\n
\n

You are currently viewing a placeholder content from YouTube<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p>\n

More Information<\/a> <\/div>\n

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div><\/div><\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_empty_space height=”44px”][\/vc_column][\/vc_row][vc_row][vc_column el_class=”gco-layout-container-column” offset=”vc_col-lg-9″][vc_column_text css=”.vc_custom_1635325797215{margin-bottom: 16px !important;}” el_class=”gco-event-subhead-accordeon”]Speakers[\/vc_column_text][vc_row_inner][vc_column_inner el_class=”gco-layout-container-column” offset=”vc_col-lg-6″][vc_single_image image=”19613″ img_size=”122×122″ style=”vc_box_circle_2″ el_class=”gco-event-img” css=”.vc_custom_1649773460525{margin-bottom: 33px !important;}”][vc_empty_space][vc_column_text el_class=”gco-event-text-accordeon” css=”.vc_custom_1656926145278{margin-top: 22px !important;}”]Dr. MD PhD Alexander Gebauer
\n<\/strong>CEO Secarna Pharmaceuticals GmbH & Co. KG<\/p>\n

 <\/p>\n

Topic: <\/strong>LNAplus™ antisense oligonucleotides are effective and safe therapeutic modalities for a variety of diseases<\/strong><\/p>\n

The third generation of antisense molecules provides drug developers with a powerful intervention option. Secarna operates a development platform that allows lead candidates against mRNA targets to be rationally identified in a semi-industrial process. This includes in-house bioinformatics analysis, high-throughput screening, and efficacy and safety assays. Secarna has six ongoing partnerships with companies and over ten academic collaborations.[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”gco-layout-container-column” offset=”vc_col-lg-6″][vc_single_image image=”19615″ img_size=”122×122″ style=”vc_box_circle_2″ el_class=”gco-event-img” css=”.vc_custom_1649773468348{margin-bottom: 33px !important;}”][vc_empty_space][vc_column_text el_class=”gco-event-text-accordeon” css=”.vc_custom_1649774028686{margin-top: 22px !important;}”]Prof. Magdalena G\u00f6tz
\n<\/strong>Director of the Institute of Stem Cell Research at Helmholtz Zentrum M\u00fcnchen and Chair of Physiological Genomics at Ludwig-Maximilians-Universit\u00e4t Munich<\/p>\n

 <\/p>\n

Topic: A new approach to neuronal replacement therapy<\/strong><\/p>\n

Direct reprogramming of local glial cells into new neurons is a new promising approach to replace dead neurons. This approach was discovered several years ago by Prof. Goetz. She will present the current status of this innovative approach to neuronal replacement therapy at the IZBrunch.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column offset=”vc_col-lg-3″][vc_column_text css=”.vc_custom_1635325815637{margin-bottom: 16px !important;}” el_class=”gco-event-subhead-accordeon”]Welcome & Moderation[\/vc_column_text][vc_row_inner][vc_column_inner el_class=”gco-layout-container-column”][vc_single_image image=”17942″ img_size=”122×122″ style=”vc_box_circle_2″ el_class=”gco-event-img” css=”.vc_custom_1631604957892{margin-bottom: 33px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_empty_space][vc_column_text el_class=”gco-event-text-accordeon” css=”.vc_custom_1652172798860{margin-top: 22px !important;}”]Dr. Peter Hanns Zobel<\/strong>
\nManaging Director of the IZB<\/p>\n

Topic:<\/strong>
\nNews from the IZB[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n


\nDownload Invitation as PDF<\/span><\/a><\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"featured_media":0,"template":"","meta":{"_links_to":"","_links_to_target":""},"event-types":[],"class_list":["post-18313","gco_events","type-gco_events","status-publish","hentry"],"yoast_head":"\nIZBrunch November 2021 - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IZBrunch November 2021\" \/>\n<meta property=\"og:description\" content=\"SpeakersDr. MD PhD Alexander Gebauer CEO Secarna Pharmaceuticals GmbH & Co. KG   Topic: LNAplus™ antisense oligonucleotides are effective\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-05T08:41:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gco_events\\\/izbrunch-november-2021\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gco_events\\\/izbrunch-november-2021\\\/\",\"name\":\"IZBrunch November 2021 - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"datePublished\":\"2021-10-27T09:06:39+00:00\",\"dateModified\":\"2022-07-05T08:41:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gco_events\\\/izbrunch-november-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gco_events\\\/izbrunch-november-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gco_events\\\/izbrunch-november-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZBrunch November 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IZBrunch November 2021 - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/","og_locale":"en_US","og_type":"article","og_title":"IZBrunch November 2021","og_description":"SpeakersDr. MD PhD Alexander Gebauer CEO Secarna Pharmaceuticals GmbH & Co. KG   Topic: LNAplus™ antisense oligonucleotides are effective","og_url":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_modified_time":"2022-07-05T08:41:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/","url":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/","name":"IZBrunch November 2021 - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"datePublished":"2021-10-27T09:06:39+00:00","dateModified":"2022-07-05T08:41:13+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/gco_events\/izbrunch-november-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZBrunch November 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_events\/18313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_events"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/gco_events"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=18313"}],"wp:term":[{"taxonomy":"event-types","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/event-types?post=18313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}